Brief: Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial
11/03/2025 10:46
March 11 (Reuters) - Arvinas Inc ARVN.O: ARVINAS AND PFIZER ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERITAC-2 CLINICAL TRIAL ARVINAS INC - VERITAC-2 ACHIEVES PRIMARY ENDPOINT IN ESR1M POPULATION ARVINAS INC - TRIAL DID NOT REACH STATISTICAL SIGNIFICANCE IN ITT POPULATION ARVINAS INC - VEPDEGESTRANT GENERALLY WELL TOLERATED WITH CONSISTENT SAFETY PROFILE ARVINAS INC - TRIAL TO CONTINUE ASSESSING OVERALL SURVIVAL AS SECONDARY ENDPOINT Source text: ID:nGNX50VTQy Further company coverage: ARVN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology